A. Mohamedali

发表

MicroRNA expression profiling of high and low risk MDS

G. Mufti, N. Lea, B. Czepulkowski, 2009 .

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

G. Mufti, N. Lea, U. Germing, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uniparental disomy (UPD) of a novel bisphosphoglycerate mutase (BPGM) mutation leading to erythrocytosis

D. Mclornan, A. Mohamedali, I. Lazana, 2020, British journal of haematology.

Serum profiling reveals distinctive proteomic markers in chronic myeloid leukaemia patients

G. Mufti, A. Mohamedali, N. S. Thomas, 2009, British journal of haematology.

A Functional Assay for MicroRNA Target Identification and Validation

G. Mufti, F. Farzaneh, M. Tavassoli, 2010 .

Cyclin D2 controls B cell progenitor numbers

E. Lam, G. Mufti, J. Glassford, 2003, Journal of leukocyte biology.

FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity.

G. Mufti, T. Gaymes, A. Mohamedali, 2017, Cancer research.

Mutations of FLT 3 and JAK 2 promote inter chromosomal homologous recombination and the potential for copy neutral loss of heterozygosity ( CN-LOH ) in acute myeloid leukemia

G. Mufti, T. Gaymes, A. Mohamedali, 2016 .

Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten‐eleven translocation 2 mutations in budd‐chiari syndrome and their impact on thrombotic complications post Liver Transplantation

G. Mufti, N. Lea, M. Heneghan, 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

G. Mufti, P. Antunović, M. Arno, 2006, Leukemia.

Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia

G. Mufti, M. Arno, N. Lea, 2006, Leukemia.

Preclinical modeling of myelodysplastic syndromes

G. Mufti, A. Abarrategi, P. Fenaux, 2017, Leukemia.

AKT1 (E17K) Mutation in Pancreatic Cancer

G. Mufti, N. Lea, H. Kocher, 2008, Technology in cancer research & treatment.

The JAK2 V617F mutation is rare in RARS but common in RARS-T

G. Mufti, J. Cervera, N. Lea, 2006, Leukemia.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation

G. Mufti, M. Bornhäuser, A. Mohamedali, 2018, Leukemia.

p27Kip1 and p130 Cooperate To Regulate Hematopoietic Cell Proliferation In Vivo

E. Lam, K. Naresh, R. Watson, 2006, Molecular and Cellular Biology.

Functional characterization of CD4+ T cells in aplastic anemia.

G. Mufti, F. Farzaneh, T. Seidl, 2012, Blood.

Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.

G. Mufti, A. Mohamedali, Alexander Smith, 2012, Blood.

Recurrent Novel Regions of Uniparental Disomy and Homozygous Deletions in Mycosis Fungoides Identified Using High Resolution Single Nucleotide Polymorphism Analysis.

G. Mufti, S. Whittaker, R. Ireland, 2009 .

IL-2 Gene and Antisense TGF-β1 Strategies Counteract HSV-2 Transformed Tumor Progression

D. Gridley, A. Mohamedali, J. Kettering, 2003, Technology in cancer research & treatment.

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

A. Jankowska, M. McDevitt, G. Mufti, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

G. Mufti, N. Lea, T. Gaymes, 2010 .

BRIEF REPORT

G. Mufti, A. Mohamedali, Alexander Smith, 2013 .

myelodysplastic syndrome Utility of peripheral blood for cytogenetic and mutation analysis in

G. Mufti, A. Mohamedali, Alexander Smith, 2013 .

Prevalence and prognostic signiﬁcance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

G. Mufti, N. Lea, U. Germing, 2007 .

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

G. Mufti, N. Lea, T. Gaymes, 2013 .

Preclinical modeling of myelodysplastic syndromes

G. Mufti, A. Abarrategi, P. Fenaux, 2017, Leukemia.

mutations in acute myeloid leukemia promote interchromosomal homologous recombination and the potential for copy neutral loss of heterozygosity (CN-LOH)

G. Mufti, T. Gaymes, A. Mohamedali, 2017 .

Microsatellite Instability (MSI) In High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Cells Promotes Frameshift Mutations In DNA Repair Genes Indications for PARP Inhibitor Therapy

G. Mufti, T. Gaymes, S. Shall, 2010 .

A functional assay for microRNA target identification and validation

G. Mufti, F. Farzaneh, C. Chronis, 2010, Nucleic acids research.

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

G. Mufti, N. Lea, T. Seidl, 2013, Haematologica.

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

G. Mufti, A. Mohamedali, Ghulam J Mufti, 2013, British journal of haematology.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

G. Mufti, J. Maciejewski, N. Lea, 2010, Blood.

nucleotide polymorphism analysis in low risk myelodysplastic syndromes Prevalence and prognostic significance of allelic imbalance by single

G. Mufti, N. Lea, U. Germing, 2013 .

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

G. Mufti, N. Lea, U. Germing, 2007, Blood.

CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.

G. Mufti, B. Czepulkowski, R. Ireland, 2015, The Lancet. Haematology.

Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells.

E. Richard, F. Moreau-Gaudry, P. Malik, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Van‐den Berghe’s 5q‐ syndrome in 2008

A. Mohamedali, G. Mufti, 2009, British journal of haematology.

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

N. Curtin, G. Mufti, F. Farzaneh, 2013, Haematologica.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

G. Mufti, N. Lea, B. Czepulkowski, 2013, British journal of haematology.

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

A. Jankowska, M. McDevitt, G. Mufti, 2012, Blood.

BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.

I. Weissman, D. Felsher, G. Mufti, 2007, Cancer research.

Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.

G. Mufti, B. Czepulkowski, J. Gaken, 2014, Blood.

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

G. Mufti, F. Farzaneh, T. Seidl, 2013, Haematologica.

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

M. McDevitt, G. Mufti, C. O'keefe, 2011, Blood.

Immunotherapy of myeloid leukaemia

K. Mills, A. Mohamedali, B. Guinn, 2007, Cancer Immunology, Immunotherapy.

Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia

K. Mills, B. Czepulkowski, A. Mohamedali, 2007, Biomarker insights.

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

L. Arenillas, B. Ebert, B. Nilsson, 2019, Blood advances.

High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)

G. Mufti, T. Gaymes, R. Ireland, 2015, Leukemia.

Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations

G. Mufti, N. Lea, M. Heneghan, 2009 .

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

M. McDevitt, G. Mufti, C. O'keefe, 2011, Blood.

FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity.

G. Mufti, T. Gaymes, A. Mohamedali, 2017, Cancer research.